UK markets close in 3 hours 9 minutes

Grifols, S.A. (0RDV.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
10.310.00 (0.00%)
As of 03:53PM GMT. Market open.
Full screen
Previous close10.31
Open10.31
BidN/A x N/A
AskN/A x N/A
Day's range10.14 - 10.18
52-week range10.14 - 10.18
Volume2,130
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)0.68
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Grifols announces positive topline phase 3 fibrinogen clinical trial results

    In the AdFIrst study, Biotest's fibrinogen concentrate (FC), BT524, met the primary endpoint, demonstrating its effectiveness in treating acquired fibrinogen deficiency (AFD) as equivalent to standard of care, while maintaining an excellent safety profileRegulatory approval process in Europe and United States set to begin in Q4 2024. It would be the first FC approved for an AFD indication in the U.S. in a global market for AFD with an estimated potential of USD 800 millionThis milestone is part

  • PR Newswire

    Grifols launches new solution to facilitate pre-transfusion compatibility testing in multiple myeloma patients

    Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines and innovative diagnostic solutions, today announced the launch of its new Grifols sCD38 solution, the industry's first-ever soluble recombinant protein designed to block anti-CD38 antibodies in multiple myeloma patients receiving daratumumab therapy, ensuring quick and accurate blood transfusion tests that are critical for proper treatment.

  • GlobeNewswire

    Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

    Study designed to demonstrate impact of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% (Alpha-1 15%), an alpha1 antitrypsin treatment, compared with Liquid Alpha1-Proteinase Inhibitor (Human) intravenousThis first in-human subcutaneous approach to treating alpha1-antitrypsin deficiency, if proven successful in clinical trials, could give patients the convenience and flexibility to administer their medication from home BARCELONA, Spain, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, M